KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31
KYNTRA BIO, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$5.28+0.43 (+8.87%)
Close on Oct 19, 2026
- Market cap
- $21.37M
- P/E (TTM)
- 0.1
- Dividend yield
- –
Kyntra Bio statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Kyntra Bio | Industry median |
|---|---|---|
| Market Cap | $21.38M | $164.85M |
| Enterprise Value | -$69.94M | $87.06M |
| PE Ratio | 0.12 | 19.63 |
| PS Ratio | 4.63 | 3.60 |
Enterprise value
| Measure | Kyntra Bio | Industry median |
|---|---|---|
| EV / Sales | -15.15 | 2.43 |
Income (trailing twelve months)
| Measure | Kyntra Bio | Industry median |
|---|---|---|
| Revenue | $4.62M | $57.94M |
| Gross Profit | $289.00K | $90.47M |
| Operating Income | -$50.32M | -$21.44M |
| Pretax Income | -$30.92M | -$14.45M |
| Net Income | $183.19M | -$22.46M |
| EBITDA | -$50.32M | -$16.91M |
| EPS (Diluted) | $45.30 | -$0.83 |
Margins
| Measure | Kyntra Bio | Industry median |
|---|---|---|
| Gross Margin | 6.26% | 52.3% |
| Operating Margin | -1089.8% | -44.5% |
| Pretax Margin | -669.6% | -13.0% |
| Profit Margin | 3967.8% | -39.2% |
| EBITDA Margin | -1089.8% | -31.3% |
| FCF Margin | -824.4% | -8.85% |
Returns
| Measure | Kyntra Bio | Industry median |
|---|---|---|
| Return on Assets (ROA) | 131.3% | -41.0% |
| Return on Capital Employed (ROCE) | -77.4% | -37.8% |
Growth
| Measure | Kyntra Bio | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -37.1% | 6.01% |
| Revenue Growth (3Y CAGR) | -64.2% | 2.25% |
| Revenue Growth (5Y CAGR) | -48.4% | 6.42% |
Balance sheet
| Measure | Kyntra Bio | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $91.32M | $62.42M |
| Net Cash (Debt) | $91.32M | $15.68M |
| Net Cash Per Share | $22.55 | $0.66 |
| Equity (Book Value) | -$30.14M | $48.79M |
| Book Value Per Share | -$7.44 | $1.36 |
| Tangible Book Value | -$30.14M | $23.06M |
| Working Capital | $60.79M | $75.77M |
Financial position
| Measure | Kyntra Bio | Industry median |
|---|---|---|
| Current Ratio | 2.69 | 3.30 |
| Quick Ratio | 2.54 | 2.39 |
| Interest Coverage | -5.42 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Kyntra Bio | Industry median |
|---|---|---|
| Operating Cash Flow | -$38.05M | -$12.35M |
| Capital Expenditures | -$9.00K | -$1.06M |
| Free Cash Flow | -$38.06M | -$20.28M |
| FCF Per Share | -$9.40 | -$0.42 |
Efficiency
| Measure | Kyntra Bio | Industry median |
|---|---|---|
| Asset Turnover | 0.03 | 0.38 |
| Inventory Turnover | 1.19 | 2.67 |
| Revenue Per Employee | $135.79K | $398.96K |
| Profits Per Employee | $5.39M | -$703.34K |
| Employee Count | 34 | 74 |
Dividends and yields
| Measure | Kyntra Bio | Industry median |
|---|---|---|
| Earnings Yield | 856.9% | -22.7% |
| FCF Yield | -178.0% | -9.07% |
Shares
| Measure | Kyntra Bio | Industry median |
|---|---|---|
| Shares Outstanding | 4,049,120 | 58,179,650 |
| Shares Change (YoY) | 0.30% | 11.1% |
| Shares Change (QoQ) | 0.02% | 0.54% |
| Float | 3,413,770 | 49,173,100 |
| Shares Held by Insiders | 15.7% | 11.6% |
| Shares Held by Institutions | 24.7% | 59.4% |
Taxes
| Measure | Kyntra Bio | Industry median |
|---|---|---|
| Income Tax | -$1.00K | $91.50K |
Scores
| Measure | Kyntra Bio | Industry median |
|---|---|---|
| Altman Z-Score | -24.43 | -0.24 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Kyntra Bio's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.